Cargando…
Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States
Little is known about how psoriatic disease characteristics and treatment outcomes differ geographically in the United States. Our aim was to explore real-world, geographic variations in the use of biologic classes and outcomes within the Corrona Psoriasis Registry. Patient demographics and disease...
Autores principales: | Enos, Clinton W., O’Connell, Katie A., Harrison, Ryan W., McLean, Robert R., Dube, Blessing, Van Voorhees, Abby S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659388/ https://www.ncbi.nlm.nih.gov/pubmed/34909720 http://dx.doi.org/10.1016/j.xjidi.2021.100025 |
Ejemplares similares
-
Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2021) -
US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
por: Lebwohl, Mark G., et al.
Publicado: (2015) -
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry
por: Walsh, Jessica A., et al.
Publicado: (2021) -
Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options
por: Menter, Alan, et al.
Publicado: (2021) -
Psoriasis and comorbidities: links and risks
por: Ni, Catherine, et al.
Publicado: (2014)